Two-dose aflibercept 8 mg versus three-dose aflibercept 2 mg loading for treatment-naïve neovascular age-related macular degeneration.

Shirakami M, Miyata M, Hata M, Ooto S, Tamura H, Otsuka A, Tsukui L, Ueda-Arakawa N, Miyake M, Takahashi A, Kadomoto S, Muraoka Y, Tsujikawa A

Open source

DOI: 10.1371/journal.pone.0349947
Published: 2026
Container: PloS one
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1371/journal.pone.0349947,
  title = {Two-dose aflibercept 8 mg versus three-dose aflibercept 2 mg loading for treatment-naïve neovascular age-related macular degeneration.},
  author = {Shirakami M and Miyata M and Hata M and Ooto S and Tamura H and Otsuka A and Tsukui L and Ueda-Arakawa N and Miyake M and Takahashi A and Kadomoto S and Muraoka Y and Tsujikawa A},
  year = {2026},
  journal = {PloS one},
  doi = {10.1371/journal.pone.0349947},
  url = {https://doi.org/10.1371/journal.pone.0349947}
}

RIS

TY  - JOUR
TI  - Two-dose aflibercept 8 mg versus three-dose aflibercept 2 mg loading for treatment-naïve neovascular age-related macular degeneration.
AU  - Shirakami M
AU  - Miyata M
AU  - Hata M
AU  - Ooto S
AU  - Tamura H
AU  - Otsuka A
AU  - Tsukui L
AU  - Ueda-Arakawa N
AU  - Miyake M
AU  - Takahashi A
AU  - Kadomoto S
AU  - Muraoka Y
AU  - Tsujikawa A
PY  - 2026
JO  - PloS one
DO  - 10.1371/journal.pone.0349947
UR  - https://doi.org/10.1371/journal.pone.0349947
ER  -

APA

M, S., M, M., M, H., S, O., H, T., A, O., L, T., N, U., M, M., A, T., S, K., Y, M., & A, T. (2026). Two-dose aflibercept 8 mg versus three-dose aflibercept 2 mg loading for treatment-naïve neovascular age-related macular degeneration.. PloS one. https://doi.org/10.1371/journal.pone.0349947

Source records

pubmed · retrieved 2026-09-24T23:52:05.116Z